MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer

Chien Yu Cho, Kuo Ting Lee, Wei Ching Chen, Chih Yang Wang, Yung Sheng Chang, Hau Lun Huang, Hui Ping Hsu, Meng Chi Yen, Ming Zong Lai, Ming Derg Lai

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

MST3 (mammalian STE20-like kinase 3) belongs to the Ste20 serine/threonine protein kinase family. The role of MST3 in tumor growth is less studied; therefore, we investigates the function of MST3 in breast cancer. Here, we demonstrate that MST3 is overexpressed in human breast tumors. Online Kaplan-Meier plotter analysis reveals that overexpression of MST3 predicts poor prognosis in breast cancer patients. Knockdown of MST3 with shRNA inhibits proliferation and anchorage-independent growth in vitro. Downregulation of MST3 in triple-negative MDA-MB-231 and MDA-MB-468 breast cancer cells decreases tumor formation in NOD/SCID mice. MST3 interacts with VAV2, but not VAV3, as demonstrated by co-immunoprecipitation and confocal microscopy. By domain mapping of MST3, we determine that the proline-rich region of MST3 (353KDIPKRP359) interacts with the SH3 domain of VAV2. Mutation of the two proline residues in this domain significantly attenuates the interaction between MST3 and VAV2. Overexpression of wild-type MST3 (WT-MST3), but not proline-rich-deleted MST3 (ΔP-MST3), enhances the proliferation rate and anchorage-independent growth of MDA-MB-468 cells. Overexpression of MST3 increases VAV2 phosphorylation and GTP-Rac1, whereas downregulation of MST3 or delivery of ΔP-MST3 results in a reduction of VAV2 and Rac1 activation. Knockdown of MST3 inhibits cyclin D1 protein expression. The Rac1 inhibitor EHop-016 attenuates cell proliferation induced by WT-MST3. Finally, Knockdown of MST3 or Rac1 inhibitor decreases cyclin D protein expression, which is important for tumor growth. These results indicate that MST3 interacts with VAV2 to activate Rac1 and promote the tumorigenicity of breast cancer.

Original languageEnglish
Pages (from-to)14586-14604
Number of pages19
JournalOncotarget
Volume7
Issue number12
DOIs
Publication statusPublished - Mar 22 2016
Externally publishedYes

Fingerprint

Cyclin D1
Phosphotransferases
Breast Neoplasms
Proline
Growth
Down-Regulation
Cyclin D
Neoplasms
Inbred NOD Mouse
src Homology Domains
SCID Mice
Protein-Serine-Threonine Kinases

Keywords

  • Breast cancer
  • Cyclin D1
  • MST3
  • Rac1
  • VAV2

ASJC Scopus subject areas

  • Oncology

Cite this

Cho, C. Y., Lee, K. T., Chen, W. C., Wang, C. Y., Chang, Y. S., Huang, H. L., ... Lai, M. D. (2016). MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer. Oncotarget, 7(12), 14586-14604. https://doi.org/10.18632/oncotarget.7542

MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer. / Cho, Chien Yu; Lee, Kuo Ting; Chen, Wei Ching; Wang, Chih Yang; Chang, Yung Sheng; Huang, Hau Lun; Hsu, Hui Ping; Yen, Meng Chi; Lai, Ming Zong; Lai, Ming Derg.

In: Oncotarget, Vol. 7, No. 12, 22.03.2016, p. 14586-14604.

Research output: Contribution to journalArticle

Cho, CY, Lee, KT, Chen, WC, Wang, CY, Chang, YS, Huang, HL, Hsu, HP, Yen, MC, Lai, MZ & Lai, MD 2016, 'MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer', Oncotarget, vol. 7, no. 12, pp. 14586-14604. https://doi.org/10.18632/oncotarget.7542
Cho, Chien Yu ; Lee, Kuo Ting ; Chen, Wei Ching ; Wang, Chih Yang ; Chang, Yung Sheng ; Huang, Hau Lun ; Hsu, Hui Ping ; Yen, Meng Chi ; Lai, Ming Zong ; Lai, Ming Derg. / MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer. In: Oncotarget. 2016 ; Vol. 7, No. 12. pp. 14586-14604.
@article{00e6b96e61304077a47897dcb9afe3ab,
title = "MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer",
abstract = "MST3 (mammalian STE20-like kinase 3) belongs to the Ste20 serine/threonine protein kinase family. The role of MST3 in tumor growth is less studied; therefore, we investigates the function of MST3 in breast cancer. Here, we demonstrate that MST3 is overexpressed in human breast tumors. Online Kaplan-Meier plotter analysis reveals that overexpression of MST3 predicts poor prognosis in breast cancer patients. Knockdown of MST3 with shRNA inhibits proliferation and anchorage-independent growth in vitro. Downregulation of MST3 in triple-negative MDA-MB-231 and MDA-MB-468 breast cancer cells decreases tumor formation in NOD/SCID mice. MST3 interacts with VAV2, but not VAV3, as demonstrated by co-immunoprecipitation and confocal microscopy. By domain mapping of MST3, we determine that the proline-rich region of MST3 (353KDIPKRP359) interacts with the SH3 domain of VAV2. Mutation of the two proline residues in this domain significantly attenuates the interaction between MST3 and VAV2. Overexpression of wild-type MST3 (WT-MST3), but not proline-rich-deleted MST3 (ΔP-MST3), enhances the proliferation rate and anchorage-independent growth of MDA-MB-468 cells. Overexpression of MST3 increases VAV2 phosphorylation and GTP-Rac1, whereas downregulation of MST3 or delivery of ΔP-MST3 results in a reduction of VAV2 and Rac1 activation. Knockdown of MST3 inhibits cyclin D1 protein expression. The Rac1 inhibitor EHop-016 attenuates cell proliferation induced by WT-MST3. Finally, Knockdown of MST3 or Rac1 inhibitor decreases cyclin D protein expression, which is important for tumor growth. These results indicate that MST3 interacts with VAV2 to activate Rac1 and promote the tumorigenicity of breast cancer.",
keywords = "Breast cancer, Cyclin D1, MST3, Rac1, VAV2",
author = "Cho, {Chien Yu} and Lee, {Kuo Ting} and Chen, {Wei Ching} and Wang, {Chih Yang} and Chang, {Yung Sheng} and Huang, {Hau Lun} and Hsu, {Hui Ping} and Yen, {Meng Chi} and Lai, {Ming Zong} and Lai, {Ming Derg}",
year = "2016",
month = "3",
day = "22",
doi = "10.18632/oncotarget.7542",
language = "English",
volume = "7",
pages = "14586--14604",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "12",

}

TY - JOUR

T1 - MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer

AU - Cho, Chien Yu

AU - Lee, Kuo Ting

AU - Chen, Wei Ching

AU - Wang, Chih Yang

AU - Chang, Yung Sheng

AU - Huang, Hau Lun

AU - Hsu, Hui Ping

AU - Yen, Meng Chi

AU - Lai, Ming Zong

AU - Lai, Ming Derg

PY - 2016/3/22

Y1 - 2016/3/22

N2 - MST3 (mammalian STE20-like kinase 3) belongs to the Ste20 serine/threonine protein kinase family. The role of MST3 in tumor growth is less studied; therefore, we investigates the function of MST3 in breast cancer. Here, we demonstrate that MST3 is overexpressed in human breast tumors. Online Kaplan-Meier plotter analysis reveals that overexpression of MST3 predicts poor prognosis in breast cancer patients. Knockdown of MST3 with shRNA inhibits proliferation and anchorage-independent growth in vitro. Downregulation of MST3 in triple-negative MDA-MB-231 and MDA-MB-468 breast cancer cells decreases tumor formation in NOD/SCID mice. MST3 interacts with VAV2, but not VAV3, as demonstrated by co-immunoprecipitation and confocal microscopy. By domain mapping of MST3, we determine that the proline-rich region of MST3 (353KDIPKRP359) interacts with the SH3 domain of VAV2. Mutation of the two proline residues in this domain significantly attenuates the interaction between MST3 and VAV2. Overexpression of wild-type MST3 (WT-MST3), but not proline-rich-deleted MST3 (ΔP-MST3), enhances the proliferation rate and anchorage-independent growth of MDA-MB-468 cells. Overexpression of MST3 increases VAV2 phosphorylation and GTP-Rac1, whereas downregulation of MST3 or delivery of ΔP-MST3 results in a reduction of VAV2 and Rac1 activation. Knockdown of MST3 inhibits cyclin D1 protein expression. The Rac1 inhibitor EHop-016 attenuates cell proliferation induced by WT-MST3. Finally, Knockdown of MST3 or Rac1 inhibitor decreases cyclin D protein expression, which is important for tumor growth. These results indicate that MST3 interacts with VAV2 to activate Rac1 and promote the tumorigenicity of breast cancer.

AB - MST3 (mammalian STE20-like kinase 3) belongs to the Ste20 serine/threonine protein kinase family. The role of MST3 in tumor growth is less studied; therefore, we investigates the function of MST3 in breast cancer. Here, we demonstrate that MST3 is overexpressed in human breast tumors. Online Kaplan-Meier plotter analysis reveals that overexpression of MST3 predicts poor prognosis in breast cancer patients. Knockdown of MST3 with shRNA inhibits proliferation and anchorage-independent growth in vitro. Downregulation of MST3 in triple-negative MDA-MB-231 and MDA-MB-468 breast cancer cells decreases tumor formation in NOD/SCID mice. MST3 interacts with VAV2, but not VAV3, as demonstrated by co-immunoprecipitation and confocal microscopy. By domain mapping of MST3, we determine that the proline-rich region of MST3 (353KDIPKRP359) interacts with the SH3 domain of VAV2. Mutation of the two proline residues in this domain significantly attenuates the interaction between MST3 and VAV2. Overexpression of wild-type MST3 (WT-MST3), but not proline-rich-deleted MST3 (ΔP-MST3), enhances the proliferation rate and anchorage-independent growth of MDA-MB-468 cells. Overexpression of MST3 increases VAV2 phosphorylation and GTP-Rac1, whereas downregulation of MST3 or delivery of ΔP-MST3 results in a reduction of VAV2 and Rac1 activation. Knockdown of MST3 inhibits cyclin D1 protein expression. The Rac1 inhibitor EHop-016 attenuates cell proliferation induced by WT-MST3. Finally, Knockdown of MST3 or Rac1 inhibitor decreases cyclin D protein expression, which is important for tumor growth. These results indicate that MST3 interacts with VAV2 to activate Rac1 and promote the tumorigenicity of breast cancer.

KW - Breast cancer

KW - Cyclin D1

KW - MST3

KW - Rac1

KW - VAV2

UR - http://www.scopus.com/inward/record.url?scp=84971634594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971634594&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7542

DO - 10.18632/oncotarget.7542

M3 - Article

C2 - 26910843

AN - SCOPUS:84971634594

VL - 7

SP - 14586

EP - 14604

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 12

ER -